Development and Validation of a High Performance Thin Layer Chromatographic Method for Quantitative Analysis of Saxagliptin
- 1 University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
- 2 University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
- 3 University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
Abstract
A simple, specific, accurate and precise high performance thin layer chromatographic method (HPTLC) was developed for the quantitative analysis of Saxagliptin in active pharmaceutical ingredients (APIs) and pharmaceutical dosage forms. The method was achieved using silica gel aluminum plate 60 F 254 (10 × 10 cm) as stationary phase and Methanol:Chloroform (6:4 v/v) as mobile phase. The developed plate was scanned densitometrically using UV 222 nm wavelength. The R f value of Saxagliptin was found to be 0.50 ± 0.02. The developed method was validated according to ICH guidelines. Limit of detection (LOD) and limit of quantification (LOQ) of Saxagliptin by this method were found as 7.96 ng/spot and 26.54 ng/spot, respectively. The method was found to be sensitive, specific, linear, accurate, precise and robust for the quantitative analysis of Saxagliptin in both APIs and marketed tablet formulation.
- Li, C.J., Liu, X.J., Bai, L., Yu, Q., Zhang, Q.M., Yu, P. and Yu, D.M. (2014) Efficacy and Safety of Vildagliptin, Saxagliptin or Sitagliptin as Add-On Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Dual Combination of Traditional Oral Hypoglycemic Agents. Diabetology & Metabolic Syndrome, 6, 1-9. http://dx.doi.org/10.1186/1758-5996-6-69
- Qaseem, A., Linda, L.H., Donna, E.S., Melissa, S. and Paul, S. (2012) Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine, 156, 218-231. http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00011
- Saine, M.E., Carbonari, D.M., Newcomb, C.W., Melissa, S.N., Kevin, H., Vincent, L.R., et al. (2015) Determinants of Saxagliptin Use among Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-Diabetic Drugs. BMC Pharmacology and Toxicology, 16, 1-16. http://dx.doi.org/10.1186/s40360-015-0007-z
- Scheen, A.J., Charpentier, G., Ostgren, C.J., Hellqvist, A. and Gause-Nilsson, I. (2010) Efficacy and Safety of Saxagliptin in Combination with Metformin Compared with Sitagliptin in Combination with Metformin in Adult Patients with Type 2 Diabetes Mellitus. Diabetes Metabolism Research and Reviews, 26, 540-549. http://dx.doi.org/10.1002/dmrr.1114
- Deacon, C.F. (2011) Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes: A Comparative Review. Diabetes, Obesity and Metabolism, 13, 7-18. http://dx.doi.org/10.1111/j.1463-1326.2010.01306.x
- Michael, E.C. and Robert, F. (2012) Saxagliptin for the Treatment of Type 2 Diabetes Mellitus: Assessing Cardiovascular Data. Cardiovascular Diabetology, 11, 1-8.
- Sravana Kumara, K. and Sailaja, B. (2015) Analytical Method Development and Validation for Estimation of Dipeptidyl Peptidase-4 Inhibitors: A Review. International Journal of Current Research in Chemistry and Pharmaceutical Sciences, 2, 83-98.
- Kalaichelvi, R. and Jayachandran, E. (2011) Validated Spectroscopic Method for estimation of Saxagliptin in Pure and from Tablet Formulation. International Journal of Pharmacy and Pharmaceutical Sciences, 3, 179-180.
- Ramalingam, K. and Jayachandran, E. (2012) Extractive Spectrophotometric Estimation of Saxagliptin in Pure and in Pharmaceutical Dosage Form. American Journal of Pharma Tech Research, 2, 429-433.
- Serife, E.K.T., Mustafa, V.K. and Demet, D. (2013) An HPLC Method for the Determination of Saxagliptin in Human Plasma with Fluorescence Detection. Journal of Advances in Chemistry, 3, 810-818.